We’d love to hear your feedback on this activity. It helps us to continually improve our products.
touchREVIEWS in RMD. 2024;3(2):Online ahead of journal publication
International experts from the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) have recently partnered to produce the much-anticipated classification criteria for antiphospholipid syndrome (APS), which were published in Arthritis & Rheumatology in August 2023.1 Prior to the publication of the new ACR/EULAR APS classification criteria, research studies used the Sapporo criteria, […]
Chronic back pain (CBP), defined as back pain lasting for 3 months or more, is the most common pain condition globally.1 Greater healthcare utilization, productivity limitations and poor quality of life have immediate and long-term impacts on patients and the healthcare system.2 The guidelines recommend physiotherapy as a frontline intervention, alongside education and behavioural interventions.3 […]
Welcome to the latest edition of touchREVIEWS in RMD! We’re excited to share a dynamic collection of articles that highlight the evolving landscape of rheumatic and musculoskeletal diseases (RMDs). We open the issue by delving into a series of editorials offering expert insights and critical analyses on recent developments and key issues in the field. […]
touchREVIEWS in RMD. 2024;3(1):43
This corrects the article: “Gheriani GA, Tuetken R and Lenert P. Lane–Hamilton Syndrome: A Vasculitis Mimic Presenting with Diffuse Alveolar Haemorrhage and Positive ANCA Testing. touchREVIEWS in RMD. 2024;3(1):37–42” The patient consent statement was added incorrectly due to an editorial error. The correct patient informed consent statement, provided by the authors, is included below. “Written […]
touchREVIEWS in RMD. 2024;3(1):31–36
It is increasingly recognized that autoimmune rheumatic diseases (ARDs) can affect people of any age, starting from early childhood and continuing until later in life. Furthermore, in recent decades, it has become apparent that Sjögren disease (SjD), commonly diagnosed in women aged 35–50 years old, can also affect men of all ages, as well as […]
touchREVIEWS in RMD. 2024;3(1):2–7
This editorial outlines a clinical approach to patients with periodic inflammation of unknown origin despite initial rational and targeted investigation. The focus of the editorial is on the recognition and diagnosis of systemic autoinflammatory diseases (SAIDs). Although rare, SAIDs are valuable diagnoses given they carry a risk of disease-associated damage and are often treatable. The authors […]
touchREVIEWS in RMD. 2024;3(1):21–30
The global burden of disease is heavily impacted by the increased prevalence of chronic inflammatory rheumatic diseases (CIRDs [rheumatoid arthritis (RA), spondyloarthritis (SpA), connective tissue diseases (CTDs) crystal arthropathies and polyarticular osteoarthritis (OA)]), which are prevalent chronic non-communicable diseases associated with pain, functional impairment, and years lived with disability (YLDs).1–4 Comorbidities associated with CIRDs contribute […]
touchREVIEWS in RMD. 2024;3(1):8–9
Systemic lupus erythematosus (SLE) predominantly affects females and is characterized by multisystem involvement.1,2 Despite advancements in therapeutics, patients with SLE still experience poor health-related quality of life (HRQoL).3 Systemic sclerosis (SSc) is characterized by vasculopathy and fibrosis of the skin and visceral organs.4 Like SLE, SSc contributes to a high morbidity burden and negatively impacts patients’ HRQoL.4 Non-pharmacological […]
touchREVIEWS in RMD. 2024;3(1):37–42
Diffuse alveolar haemorrhage (DAH) is associated with high morbidity and mortality. The causes of DAH are diverse, and include rheumatologic conditions such as granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), Systemic lupus erythematosus (SLE) and Goodpasture’s syndrome (Table 1). Rheumatologists are frequently consulted, given the high degree of suspicion for these underlying aetiologies. Another possible […]
Get the latest clinical insights from touchIMMUNOLOGY